Circulating transforming growth factor-β1 levels and the risk for kidney disease in African-Americans

Manikkam Suthanthiran, M.D.1, Linda M. Gerber, Ph.D.1,2, Joseph E. Schwartz, Ph.D.1,3, Vijay K. Sharma, Ph.D.1, Mara Medeiros, M.D.1, RoseMerie Marion, N.P.1, Thomas G. Pickering, M.D.4, and Phyllis August, M.D., M.P.H.1,2,5

1Department of Medicine, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY 10065
2Department of Public Health, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY 10065
3Department of Psychiatry, Stony Brook University, Stony Brook, NY 11794
4Department of Medicine, Columbia University Medical Center, New York-Presbyterian Hospital, New York, NY 10032
5The New York Hospital Queens Lang Center of Research and Education, New York, NY 11355

Abstract

Transforming growth factor-β1 (TGF-β1) is well known to induce progression of experimental renal disease. Here we determined whether there is an association between serum levels of TGF-β1 and the risk factors for progression of clinically relevant renal disorders in 186 black and 147 white adults none of whom had kidney disease or diabetes. Serum TGF-β1 protein levels were positively and significantly associated with plasma renin activity along with the systolic and diastolic blood pressure in blacks but not whites after controlling for age, gender and body mass index. These TGF-β1 protein levels were also significantly associated with body mass index and metabolic syndrome and more predictive of microalbuminuria in blacks than in whites. The differential association between TGF-β1 and renal disease risk factors in blacks and whites suggests an explanation for the excess burden of end-stage renal disease in the black population but this requires validation in an independent cohort. Whether these findings show that it is the circulating levels of TGF-β1 that contributes to renal disease progression or reflects other unmeasured factors will need to be tested in longitudinal studies.
INTRODUCTION

Transforming growth factor beta1 (TGF-β1), a prominent member of a superfamily of proteins, regulates cell growth and differentiation, inflammation and immunity. TGF-β1 is a fibrogenic cytokine that plays a key role in the pathogenesis of renal disease, and TGF-β1 blockade may prevent renal disease progression.

Blockade of the renin angiotensin system (RAS) is an important therapeutic strategy for prevention of the progression of renal disease, and experimental as well as clinical studies have shown that the benefits of RAS blockade may be in part related to the strong bidirectional relationship between the RAS and TGF-β. Antonipillai et al reported that TGF-β1, at picomolar concentrations, promotes the secretion of renin by rat juxtaglomerular cells. Brezniceanu and colleagues showed that active human TGF-β1 induces angiotensinogen gene expression in murine proximal tubular epithelial cells. It has also been reported that both renin and angiotensin II stimulate TGF-β1 expression. Huang et al. demonstrated that human or rat recombinant renin, at physiological concentrations, induces TGF-β1 and other members of the fibrotic cascade in human/rat mesangial cells via a renin receptor dependent and enzymatic and angiotensin II independent, mechanism. Wolf and colleagues reported that addition of angiotensin II to murine proximal tubular (MCT) cells induced TGF-β1 mRNA expression and synthesis and release of active TGF-β1 protein and that the growth promoting effects of angiotensin II on the cultured MCT can be accomplished with the addition of TGF-β1 to the MCT cells. In the clinical setting, drugs which block the RAS and prevent renal disease progression reduce serum levels of TGF-β1 protein.

Hypertension affects over 1 billion individuals worldwide and is a leading risk factor for end-stage kidney disease (ESRD). Hypertension is more prevalent in blacks, and renal disease progression and ESRD are more frequent in blacks compared to other ethnic/racial groups.

We have reported that blacks with hypertension and ESRD have higher circulating levels of TGF-β1 protein compared to whites. One potential explanation for the excess burden of ESRD in blacks is an increased levels and/or biologic activity of TGF-β1 in blacks compared to whites. In the current study, we investigated the association between TGF-β1 protein levels and risk factors for renal disease progression in adult black or white subjects and report that peripheral blood TGF-β1 protein levels are positively associated with PRA, systolic blood pressure, diastolic blood pressure, BMI and MBS in blacks, but not in whites. We also report that TGF-β1 protein levels are more predictive of microalbuminuria in blacks than in whites.

RESULTS

STUDY PARTICIPANTS

The demographic and clinical characteristics of study participants, stratified by race and hypertension status, are shown in Table 1. The mean (±SD) age of the 333 study subjects was 45.2 ± 10.6 years, and there were 186 blacks and 147 whites; the black participants...
were 4.7 years younger (P=0.0001) and more frequently female (P=0.005). The mean (±SD) BMI was high in both groups (29.3 ± 6.1 kg/m² for the entire cohort), but higher in blacks than whites (30.0 vs. 28.4 kg/m², P=0.01) and higher in females than males (29.8 vs. 28.5 kg/m², P=0.05). The differences between black and white subsamples with respect to the percentages of individuals classified as overweight (25–30 kg/m²) or obese were not significant (≥20 kg/m²) (P=0.14). 37.6% of the blacks and 46.3% of the whites were hypertensive as defined by average clinic BP ≥140/90 mmHg or being on antihypertensive medication (P=0.11); 74% of the hypertensives had stage 1 hypertension (140–159/90–100 mm Hg), and 54% of hypertensives were on treatment for hypertension when they enrolled in the study; the latter were withdrawn from all antihypertensive medications for a minimum of two weeks prior to evaluation and collection of biologic specimens for laboratory studies including the serum collection for measure TGF-β1 concentration. Black and white subjects had similar 24-hr urine sodium excretion, urinary albumin to creatinine excretion ratio, and prevalence of metabolic syndrome.

**TGF-β1, PRA, and Sodium Excretion**

Serum total (active plus latent) TGF-β1 protein levels were measured in 333 adults (186 blacks and 147 whites) without kidney disease or diabetes, and were higher in blacks compared to whites, higher in hypertensives than in normotensives, and highest in black hypertensives (Table 1, P=0.01), confirming and extending our earlier findings from an independent study comprised of 61 hypertensives and 90 normal controls. In this and all subsequent analyses, TGF-β1 protein levels were square-root transformed in order to reduce the substantial positive skew and make the distribution approximately normal. The 10th and 90th percentiles of TGF-β1 protein concentration in the full sample were 26.52 and 55.12 ng/ml, respectively.

We also measured active TGF-β1 protein concentration in sera from 147 of the 333 subjects assayed for total TGF-β1 protein. The 147 specimens were selected on the basis of their availability. We found that 93% of the clinical specimens did not have measurable levels of active TGF-β1 protein, and the mean (±SE) level was 12.45 ± 2.32 ng/ml in the 11 (7%) specimens that were positive. Among the sera tested for active TGF-β1 protein, measurable levels of active TGF-β1 were observed in two of 35 black normotensives (5.7%, 11.89 ± 1.64 ng/ml), 4 of 56 black hypertensives (7.1%, 6.71 ± 3.57), 2 of 30 white normotensives, (6.7%, 13.59 ± 1.44 ng/ml), and 3 of 37 white hypertensives (8.1%, 19.75 ± 4.75 ng/ml).

PRA was lower in blacks compared with whites (Table 1, P=0.0001), an observation that has also been made by others. Among the 4 groups shown in Table 1, PRA was lowest in black hypertensives compared to the three other groups, consistent with previous reports of a low-renin profile in black hypertensives [REF].

TGF-β1 protein concentration was positively associated with (log-transformed) PRA in the entire cohort (P=0.005, adjusted for race, sex, age and BMI); however, addition of a race-by-TGF-β1 protein revealed that this association was only present in blacks, with those at the 90th percentile predicted to have 3.24 [=exp(1.17), P=0.0001] times the level of PRA as those at the 10th percentile of protein; the projected ratio of PRA between whites at the two extreme deciles was only 1.09 [=exp(0.09), P=0.71] (Table 2A). The difference between
blacks and whites in the relationship of PRA to TGF-β1 protein concentration was significant (Table 2A, P=0.0007 for the race-by-TGF-β1 protein interaction term).

The bivariate relationship between PRA and TGF-β1 protein concentration, without adjustment for sex, age, or BMI, is shown in Figures 1A (blacks) and 1B (whites). The difference in PRA between blacks and whites is large at low values of TGF-β1, and negligible at high values of TGF-β1 protein concentration.

As noted above, 24-hour urinary sodium excretion rate was not different between blacks and whites (P=0.34). However, although TGF-β1 protein concentration exhibited a non-significant negative association with sodium excretion in blacks and a non-significant positive association in whites (Table 2A), the difference in the association between blacks and whites, controlling for sex, age, and BMI, was nearly significant (P=0.06).

**TGF-β1 AND BLOOD PRESSURE**

TGF-β1 protein concentration, adjusted for race, sex, age and BMI, was weakly associated with systolic blood pressure in the group as a whole (6.4 mmHg inter-decile difference [IDD=predicted difference between those at the 90th and 10th percentiles of TGF-β1 protein concentration], P=0.02), but addition of the race interaction term again revealed that this association was primarily evident in black and not white subjects (IDD=9.5 mmHg; P = 0.009 for blacks; IDD=2.3 mmHg; P=0.58 for whites; Table 2A and Figures 2A & 2B). This race dependent association was also observed for diastolic blood pressure (IDD=4.7 mmHg; P=0.03 for blacks; IDD=1.5 mmHg; P=0.56 for whites; Figure 2C & 2D). For both systolic and diastolic measures, the covariate adjusted relationship of clinic blood pressure with TGF-β1 protein was more than three times greater in blacks compared to whites, although the difference between racial groups (interaction term) was not statistically significant (Table 2A). Mean arterial pressure exhibited the same pattern as systolic and diastolic blood pressure [not shown]. Pulse pressure was also related to TGF-β1 protein in blacks (P=0.05), but not whites (P=0.77).

**TGF-β1 AND MICROALBUMINURIA**

Six percent of blacks and 5.1% of whites had microalbuminuria. As expected, the proportion with microalbuminuria was higher in hypertensives compared with normotensives (Table 1), although the majority of these mild hypertensives did not have microalbuminuria. Controlling for sex, race and BMI in a logistic regression analysis, TGF-β1 was significantly associated with microalbuminuria overall, and in blacks, but not in whites. The predicted odds ratio for the presence of microalbuminuria between a black subject at the 90th compared to someone at the 10th percentile of TGF-β1 protein levels, was 6.6 (95% CI: 1.4, 31.1; P=0.02) whereas for whites it was 2.4 (0.3, 19.0; P=0.39) (Table 2B). Despite the association being substantially stronger in blacks than whites, the interaction was not statistically significant (Table 2B, P=0.45).

**TGF-β1 AND BMI**

TGF-β1 was positively associated with BMI, controlling for race, sex and age, overall (B=2.0 kg/m² IDD, P=0.02), and for blacks (B=2.5 kg/m² IDD, P=0.03) but not whites.
TGF-β1 AND METABOLIC SYNDROME

Subjects were characterized based on the number of features (0–5) of MBS (elevated BP, increased waist circumference, elevated triglycerides, elevated fasting glucose, and low HDL cholesterol) present, and also whether they had 3 or more criteria for MBS. There was little difference between the blacks and whites in either the number of features of MBS or the proportion of participants with 3 or more criteria for MBS. TGF-β1 protein levels were significantly associated with number of features of MBS (in an ordered probit analysis) as well as the presence of MBS (logistic analysis), controlling for sex, age, and race. Inclusion of the race interaction term again revealed that the association with number of MBS features was strong in blacks (P=0.0001), but only marginal in whites (P=0.07, Table 2A). Similarly, the predicted odds of meeting criteria for MBS (having 3 or more criteria) was 4.5 (95% CI: 1.0, 19.9; P=0.04; Table 2B) for blacks at the 90th percentile of TGF-β1 concentration compared to those at the 10th percentile, and 3.0 (0.8, 11.6; P=0.11) for whites. The associations in blacks were stronger, but not significantly stronger, than those in whites (Table 2A and 2B).

DISCUSSION

Hypertension and ESRD are increasing in prevalence worldwide, and both conditions are more common in blacks compared to whites. We report a positive association, primarily in blacks, between circulating TGF-β1 protein concentration and plasma renin activity, blood pressure, microalbuminuria, BMI and MBS. Our findings suggest that TGF-β1, a known mediator of renal disease, may modulate multiple renal risk factors, and may be biologically more active in blacks compared to whites.

An earlier study has shown that TGF-β1, at picomolar concentrations, induces the secretion of renin by rat renal juxtaglomerular cells. Our study showing that TGF-β1 levels are positively associated with PRA, to the best of our knowledge, is the first clinical study reporting a positive relationship between TGF-β1 and the renin angiotensin system (RAS) in humans. The association of TGF-β1 and renin may be mechanistically relevant for fibrosis, vascular pathology and the progression of renal disease.

The positive association between TGF-β1 and PRA in blacks is intriguing, and may even appear paradoxical, since PRA levels are lower in blacks compared to whites, and lowest in the black hypertensives, and serum TGF-beta1 levels are higher in blacks compared to whites and highest in the black hypertensives. A linear and close looped relationship between TGF-β1 and PRA in blacks would predict that blacks would have a higher level of PRA compared to whites. One potential explanation that can account for the lower PRA in blacks despite a higher TGF-β1 is that TGF-β1 not only stimulates renin secretion but also has an additional and stimulatory effect on sodium reabsorption by the kidney, and the increased sodium (and water) reabsorption results in renin suppression and low renin hypertension (a well documented form of hypertension in the black population). Partial
support for this concept is provided by our findings that 24 hour urine sodium excretion is lowest in the black hypertensives (Table 1), and the association between 24 hour urine sodium excretion and TGF-β1 protein levels is negative in blacks and positive in whites (Table 2). Additional measurements of the response of blood pressure, PRA and TGF-β1 to salt loading should help clarify our observations. It is note worthy that TGF-β1 has been reported to increase the activity of serine/threonine kinase, SGK\textsuperscript{23}, a kinase is expressed in several tissues\textsuperscript{24} including the sodium reabsorption sites in the human kidney\textsuperscript{25}. Importantly, SGK from Xenopus as well as from humans have been shown to increase the activities of the two sodium channels located in the distal tubule and ascending thick limb of loop of Henle, the epithelial sodium channel activity and the sodium, potassium, and chloride co-transporter\textsuperscript{26,27}.

The positive association between TGF-β1 and PRA in blacks may also result from renin or angiotensin II functioning as the stimulus for TGF-β1 synthesis and secretion. Huang et al. observed that human or rat recombinant renin, at physiological concentrations, induces TGF-β1 via a renin receptor dependent mechanism.\textsuperscript{10} Our study does not resolve whether the observed and positive association results from TGF-β1 stimulating renin release, renin or Ang II inducing TGF-β1 secretion, or due to mutual stimulation as documented in pre-clinical models\textsuperscript{7–11}. Irrespective of the directionality, it is worth emphasizing that the positive association between TGF-β1 and renin was observed only in blacks and not in whites.

Experimental studies suggest a causative role for TGF-β in vascular remodeling, blood pressure regulation, and renal disease progression\textsuperscript{28}. Anti-TGF-β antibodies lower blood pressure, reduce proteinuria and prevent renal function decline in rats\textsuperscript{29}. Deletion of the gene for Emilin-1, a negative regulator of TGF-β1, results in greater availability of TGF-β1, increased peripheral vascular resistance and increased blood pressure in mice\textsuperscript{30}. Moreover, inactivation of a single TGF-β1 allele normalizes blood pressure in the Emilin-deficient mice\textsuperscript{30}. Our new observations, in addition to confirming and extending a quantitative difference in TGF-β1 protein levels between normotensives and hypertensives, advances the hypothesis that a \textit{qualitative} difference may exist between blacks and whites in the association between TGF-β1 levels and blood pressure.

Body mass and blood pressure are positively associated in both blacks and whites; however, the age-adjusted prevalence of hypertension is greater in blacks compared to whites for BMI ranging from 18.5 to greater than 31\textsuperscript{31}. The association of TGF-β1 with both blood pressure and BMI in blacks may partially explain the increased risk of hypertension for a given level of BMI in blacks, as well as previously reported associations between BMI and ESRD\textsuperscript{32,33}.

MBS, a proinflammatory and prothrombotic disorder, increases risk for cardiovascular disease as well as kidney failure\textsuperscript{34}. Neither the average number of criteria for MBS nor the prevalence of metabolic syndrome differed between blacks and whites in our study, but the positive association of TGF-β1 concentration with both prevalence of MBS and the number of features of MBS was observed only in blacks. TGF-β1 increases plasminogen activator inhibitor (PAI)\textsubscript{1} production\textsuperscript{35}, a causal factor in the development of insulin resistance, type 2 diabetes, and associated cardiovascular complications. On the other hand, adipose tissue is
a source of increased TGF-β1 production\textsuperscript{36} and TGF-β1 concentration is greater in obese compared with non-obese hypertensives\textsuperscript{37,38}. Regardless of the direction of the relationship between TGF-β1 and MBS, TGF-β1 may be a potentially modifiable target, as well as a novel candidate genetic locus and biomarker for these important conditions, and may contribute to increased complications associated with diabetes in blacks compared to other groups.

Microalbuminuria may reflect generalized endothelial cell dysfunction as well as early renal injury. TGF-β1 concentration was positively associated with microalbuminuria only in blacks and not in whites. Our finding suggests a mechanism for the greater prevalence of hypertension associated renal damage in blacks compared to whites as well as an additional pharmacologic target for reducing albuminuria. Previous studies have indeed suggested that beneficial effects of RAS inhibition on preventing renal disease progression may be mechanistically linked both to lowering TGF-β1 levels and reducing proteinuria\textsuperscript{12,39}.

Our study has a number of limitations. Both the utility of characterizing populations based on racial/ethnic categories as well as the validity of self-identified race/ethnicity (SIRE) for stratifying populations in clinical studies have been challenged. We note in this regard that racial and ethnic differences exist in the development of ESRD in the USA\textsuperscript{15,16}. With respect to the validity of SIRE, Tang et al have recently analyzed genetic data for 326 microsatellite markers that were typed uniformly in a large multiethnic population (n=3,636) and found a near-perfect correspondence of genetic cluster analysis of microsatellite markers with the four self-reported race/ethnicity categories, white, African American, East Asian, and Hispanic\textsuperscript{40}.

Our investigation can also be criticized for not ascertaining TGF-β1 availability at the tissue/cellular level in view of the substantial post-translational regulation of TGF-β1 bioactivity\textsuperscript{41}, and differential tissue availability remains a plausible mechanism for our observations. In this regard, Huang et al. have reported renal protection by latent TGF-β in experimental mouse models of ureteral obstruction and crescentic glomerulonephritis\textsuperscript{42,43}. The intriguing hypothesis that the active version is pathogenetic whereas an excess of latent form is protective merits investigation in the clinic. We measured active as well as latent TGF-β1 in sera from a subset of subjects assayed for total TGF-β1 (active plus latent). Our observations that the active version is found in only 7% of peripheral blood specimens, and with similar frequencies in normotensives and hypertensives suggest that the presence or absence of the latent form is unlikely to explain the associations observed in our study.

In summary, we find positive associations of TGF-β1 with PRA, blood pressure, BMI, metabolic syndrome, and microalbuminuria, primarily in black subjects with either normal blood pressure or mild hypertension, and not in white subjects with similar clinical characteristics. Our findings suggest that the biologic activity of TGF-β1 is higher in blacks compared to whites. Should the significant association between TGF-β1 and mediators of renal disease in blacks be validated in an independent cohort, a new and targetable mechanism for the rapid progression and the excess burden of ESRD in the black population would emerge.
METHODS

STUDY PARTICIPANTS

We studied 333 black and white subjects with or without mild hypertension, and without overt kidney disease or cardiovascular disease. The study participants are from a cross-sectional study of race/ethnicity and blood pressure, The Neighborhood Study of Blood Pressure and Sleep\textsuperscript{44} was conducted from 1999 through 2003 at four New York City institutions – Weill Cornell Medical College, Mount Sinai School of Medicine, Harlem Hospital, and the North General Hospital – using a common protocol. The study protocol and consent form were approved by the institutional review committees for human subject research at each institution.

Participants were 18–65 years of age, had no known cardiovascular disease (CVD) or diabetes, and had no medical problems other than hypertension. Participants were asked to self-report their ethnic group/race. The mutually exclusive categories were “Black”, “White”, “Asian” or “Other…please specify”. The participants were also asked whether they considered themselves to be Spanish/Hispanic/Latino. Those who identified themselves as primarily “White” or “Black” were eligible to participate. The study participants included 186 blacks, three of whom considered themselves to also be Hispanics, and the 147 whites including 8 who considered themselves to also be Hispanic.

Subjects could be either normotensive or mildly hypertensive. Hypertension status was defined as an average clinic BP ≥140/90 mmHg at recruitment or being on antihypertensive medication. Individuals taking medication were withdrawn successfully from medication for at least 2 weeks prior to the study. Those whose BP exceeded 160/105 mmHg, before or after being withdrawn from medication, were not eligible.

BLOOD PRESSURE MEASUREMENTS

Blood pressure measurements were made by trained research personnel using a mercury sphygmomanometer according to the American Heart Association Guidelines, with patients seated and arm at heart level\textsuperscript{45}. Three readings were obtained and their average was recorded as the clinic blood pressure measure.

LABORATORY TESTS

All subjects were on ad-lib diet. All laboratory tests were performed with the biologic specimens collected at the same time, and at the time clinical blood pressure measurements were made. The specimens were collected a minimum of two-weeks following the withdrawal from antihypertensive medications. Prior to withdrawal, 10 of the 70 black hypertensives and 11 of the 68 white hypertensives were on either angiotensin converting inhibitor or angiotensin II receptor blocker.

PRA was measured using an enzyme based method and by quantification of generated Ang I by radioimmunoassay\textsuperscript{46}. Twenty-four-hour urine collections were analyzed by the Weill Cornell Medical College General Clinical Research Center for sodium, creatinine and albumin. Urinary albumin and creatinine concentrations were calculated using Bayer’s DCA.
2000® Microalbumin/Creatinine Low and High Control Kit with the company’s DCA 2000®+ Analyzer. If the albumin result was <5 mg/L, the lowest limit of detection, the concentration calculated from Diagnostic Product Corporation’s radioimmunoassay kit was used. Microalbuminuria was defined as an albumin/creatinine ratio >30 mg/gm.

**TGF- β1 PROTEIN MEASUREMENT**

Peripheral venous blood was obtained from the study participants and serum was isolated and stored at −70°C until assayed for TGF-β1 protein. Serum TGF-β1 protein concentration was measured using an isoform specific TGF-β1 ELISA according to the manufacturer’s protocol (Quantikine™ Human TGF-β1 Immunoassay, R&D Systems, Inc. Minneapolis, MN). Total TGF-β1 levels were measured after acid activation (acetic acid/urea) and neutralization (NaOH/HEPES) of serum from all 333 subjects. Active TGF-β1 (serum assayed without the activation step) was measured in all 147 available sera from the 333 subjects. A TGF-β1 standard curve was constructed by using 2000, 1,000, 500, 250, 125, 62.50, 31.25 pg/ml recombinant TGF-β1 protein, and a curve-fitting software program was used to quantify TGF-β1 protein concentration in the sera. The minimum detectable level is 7.0 pg/ml and the intra-assay and inter-assay median coefficients of variation are reported to be 5.3% and 10.9%, respectively.

**DEFINITION OF METABOLIC SYNDROME**

Metabolic syndrome (MBS) was defined according to the current recommended criteria of the National Cholesterol Education Program (Adult Treatment Panel [ATP] III) 20.

**STATISTICAL ANALYSIS**

Descriptive statistics are reported as percentages for binary/categorical measures or means and standard deviations for continuous measures; the median and quartiles are also reported for severely skewed measures. Regression analyses were used to estimate and test the relationship of serum TGF-β1 protein concentrations to PRA, blood pressure, urinary sodium excretion, BMI, microalbuminuria, and MBS; linear regression for the continuous outcome measures, logistic regression for the binary measures, and ordered probit regression for the number of metabolic syndrome criteria measure (an ordinal categorical measure ranging from 0 to 5). PRA was transformed to natural logarithms to reduce skewness and heteroskedasticity. For all regression analyses, the TGF-β1 protein measure was transformed using the square root transformation to reduce the positive skewness and make the resulting distribution approximately symmetric and normal. Regression estimates are reported as the predicted difference in the outcome between someone at the 90th percentile and someone at the 10th percentile of the TGF-β1 distribution. All analyses were performed on the full sample, with and without the inclusion of a multiplicative race-by-TGF-β1 interaction term. The inclusion of this interaction term yielded separate estimates for blacks and whites of the effect of TGF-β1, and a test of the black-white difference. Sex and age were statistically controlled for in all analyses, and BMI was controlled when predicting all outcomes except BMI and metabolic syndrome.
For the continuous outcome measures, we also estimated LOESS models for blacks and whites, in order to detect any non-linear relationships. None were found and therefore the results of the LOESS models are not presented.

ACKNOWLEDGMENTS

We are indebted to Geraldine Helseth, Mohini Gulhati and Milagros Lagman for expert technical assistance and to Linda Stackhouse and Maria Trantino for their meticulous assistance in the preparation of the manuscript.

We thank Dr. Scott Solomon for his careful review and insights.

Sources of Support

This work was supported in part by R01 DK54943 (MS), P01 HL47540 (TGP), K24 HL04268 (PA), and R24 HL76857 (TGP). This research was also supported by the Weill Cornell Medical College GCRC M01 RR00047.

REFERENCES

1. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000; 342:1350–1358. [PubMed: 10793168]
2. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994; 331:1286–1292. [PubMed: 7935686]
3. Huang Y, Border WA, Noble NA. Perspectives on blockade of TGFbeta overexpression. Kidney Int. 2006; 69:1713–1714. [PubMed: 16688190]
4. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993; 329:1456–1462. Erratum in: N Engl J Med 1993 Jan 13;330(2):152. [PubMed: 8413456]
5. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345:861–869. [PubMed: 11565518]
6. Dillon JJ. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy. Semin Nephrol. 2004; 24:218–224. [PubMed: 15156527]
7. Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension. 1998; 31(1 Pt 2):181–188. [PubMed: 9453300]
8. Antonipillai I, Le TH, Soceneantu L, Horton R. Transforming growth factor-beta is a renin secretagogue at picomolar concentrations. Am J Physiol. 1993; 265(4 Pt 2):F537–F541. [PubMed: 8238382]
9. Brezniceanu ML, et al. Transforming growth factor-beta 1 stimulates angiotensinogen gene expression in kidney proximal tubular cells. Kidney Int. 2006; 69:1977–1985. [PubMed: 16598193]
10. Huang Y, et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 2006; 69:105–113. [PubMed: 16374430]
11. Wolf G, Mueller E, Stahl RA, Ziyadeh FN. Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest. 1993; 92:1366–1372. [PubMed: 7690779]
12. Sharma K, et al. Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis. 1999; 34:818–823. [PubMed: 10561136]
13. Whelton PK, Perneger TV, He J, Klag MJ. The role of blood pressure as a risk factor for renal disease: a review of the epidemiologic evidence. J Hum Hypertens. 1996; 10:683–689. [PubMed: 9004095]
14. Kearney PM, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005; 365:217–223. [PubMed: 15652604]
15. Xue JL, Eggers PW, Agodoa LY, Foley RN, Collins AJ. Longitudinal study of racial and ethnic differences in developing end-stage renal disease among aged medicare beneficiaries. J Am Soc Nephrol. 2007; 18:1299–1306. [PubMed: 17329578]
16. Hsu CY, Lin F, Vittinghoff E, Shlipak MG. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol. 2003; 14:2902–2907. [PubMed: 14569100]
17. Newsome BB, et al. Racial differences in the competing risks of mortality and ESRD after acute myocardial infarction. Am J Kidney Dis. 2008; 52:251–261. Epub 2008 May 12. [PubMed: 18468746]
18. Suthanthiran M, et al. Transforming growth factor-beta 1 hyperexpression in African American end-stage renal disease patients. Kidney Int. 1998; 53:639–644. [PubMed: 9507209]
19. Suthanthiran M, et al. Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci U S A. 2000; 97:3479–3484. [PubMed: 10725360]
20. Grundy SM, Brewer HB Jr, Cleeman JL, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004; 109:433–438. [PubMed: 14744958]
21. Sagnella GA. Why is plasma renin activity lower in populations of African origin? J Hum Hypertens. 2001; 15:17–25. [PubMed: 11223998]
22. Ferdinand KC. Hypertension in minority populations. J Clin Hypertens (Greenwich). 2006; 8:365–368. [PubMed: 16687946]
23. Waldegger S, Klingel K, Barth P, et al. h-sgk serine-threonine protein kinase gene as transcriptional target of transforming growth factor beta in human intestine. Gastroenterology. 1999; 116:1081–1088. [PubMed: 10220500]
24. Waldegger S, Barth P, Raber G, Lang F. Cloning and characterization of a putative human serine/threonine protein kinase transcriptionally modified during anisotonic and isotonic alterations of cell volume. Proc Natl Acad Sci U S A. 1997; 94:4440–4445. [PubMed: 914008]
25. Lang F, Klingel K, Wagner CA, Stegen C, et al. Deranged transcriptional regulation of cell-volume-sensitive kinase hSGK in diabetic nephropathy. Proc Natl Acad Sci U S A. 2000; 97:8157–8162. [PubMed: 10884438]
26. Chen SY, Bhargava A, Mastroberardino L, et al. Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proc Natl Acad Sci U S A. 1999; 96:2514–2519. [PubMed: 10051674]
27. Náray-Fejes-Tóth A, Canessa C, Cleaveland ES, et al. sgk is an aldosterone-induced kinase in the renal collecting duct. Effects on epithelial na+ channels. J Biol Chem. 1999; 274:16973–16978. [PubMed: 10358046]
28. August P, Suthanthiran M. Transforming growth factor beta signaling, vascular remodeling, and hypertension. N Engl J Med. 2006; 354:2721–2723. [PubMed: 16790709]
29. Dahly AJ, et al. Antihypertensive effects of chronic anti-TGF-beta antibody therapy in Dahl S rats. Am J Physiol Regul Integr Comp Physiol. 2002; 283:R757–R767. [PubMed: 12185011]
30. Zacchigna L, et al. Emilin1 links TGF-beta maturation to blood pressure homeostasis. Cell. 2006; 124:929–942. [PubMed: 16530041]
31. Colin, Bell A.; Adair, LS.; Popkin, BM. Ethnic differences in the association between body mass index and hypertension. Am J Epidemiol. 2002; 155:346–353. [PubMed: 11836199]
32. Iseki K, et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 2002; 65:1870–1876. [PubMed: 15086929]
33. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006; 144:21–28. [PubMed: 16389251]
34. Chen J, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004; 140:167–174. [PubMed: 14757614]
35. Keeton MR, Currinden SA, van Zonneveld AJ, Loskutoff DJ. Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta. J Biol Chem. 1991; 266:23048–23052. [PubMed: 1744101]
36. Fain JN, Tichansky DS, Madan AK. Transforming growth factor beta1 release by human adipose tissue is enhanced in obesity. Metabolism. 2005; 54:1546–1551. [PubMed: 16253647]
37. Porreca E, et al. Transforming growth factor-beta1 levels in hypertensive patients: association with body mass index and leptin. Am J Hypertens. 2002; 15:759–765. [PubMed: 12219869]
38. Scaglione R, et al. Central obesity and hypertensive renal disease: association between higher levels of BMI, circulating transforming growth factor beta1 and urinary albumin excretion. Blood Press. 2003; 12:269–276. [PubMed: 14763657]
39. Scaglione R, et al. Transforming growth factor beta1 and additional renoprotective effect of combination ACE inhibitor and angiotensin II receptor blocker in hypertensive subjects with minor renal abnormalities: a 24-week randomized controlled trial. J Hypertens. 2005; 23:657–664. [PubMed: 15716710]
40. Tang H, et al. Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet. 2005; 76:268–275. [PubMed: 15625622]
41. Saharinen J, Hyttiainen M, Taipale J, Keski-Oja J. Latent transforming growth factor-beta binding proteins (LTBPs)--structural extracellular matrix proteins for targeting TGF-beta action. Cytokine Growth Factor Rev. 1999; 10:99–117. [PubMed: 10743502]
42. Huang XR, Chung AC, Wang XJ, Lai KN, Lan HY. Mice overexpressing latent TGF-beta1 are protected against renal fibrosis in obstructive kidney disease. Am J Physiol Renal Physiol. 2008; 295:F118–F127. Epub 2008 Apr 30. [PubMed: 18448597]
43. Huang XR, Chung AC, Zhou L, Wang XJ, Lan HY. Latent TGF-beta1 protects against crescentic glomerulonephritis. J Am Soc Nephrol. 2008; 19:233–242. Epub 2008 Jan 23. [PubMed: 18216320]
44. Gerber LM, Sievert LL, Warren K, et al. Hot flashes are associated with increased ambulatory systolic blood pressure. Menopause. 2007; 14:308–315. [PubMed: 17213753]
45. Pickering TG, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005; 45:142–161. [PubMed: 15611362]
46. Sealey JE. Plasma renin activity and plasma prorenin assays. Clin Chem. 1991; 37:1811–1819. [PubMed: 1914195]
Figure 1. Bivariate Relationship of Peripheral Blood Transforming Growth Factor β1 Protein Concentration to Plasma Renin Activity in Black and White Subjects

Peripheral blood total transforming growth factor β1 (TGF-β1, ng/ml) level was measured after acid activation and neutralization of serum and using an isoform specific TGF-β1 ELISA. Plasma renin activity (PRA, ng/ml/hr) was measured using an enzyme based method and by quantification of generated Ang I by radioimmunoassay. Scatterplots show the bivariate relationship of TGF-β1 protein concentrations to PRA in black subjects (Panel A) and white subjects (Panel B). TGF-β1 protein measure was transformed using the square root transformation to reduce the positive skewness and make the resulting distribution approximately symmetric. PRA was transformed to natural logarithms (ln) to reduce skewness and heteroskedasticity. Pearson correlations (r) and their associated P values are presented. The three boxes on the regression line show the predicted value of the outcome variable for subjects at the 10th, 50th, and 90th percentiles of the overall distribution of TGF-β1 protein. Numbers in parenthesis are the number of subjects studied. The symbols “o” and “x” are used to identify normotensive and hypertensive subjects.
Peripheral blood total transforming growth factor β1 (TGF-β1, ng/ml) level was measured after acid activation and neutralization of serum and using an isoform specific TGF-β1 ELISA, and transformed using the square root transformation to reduce the positive skewness and make the resulting distribution approximately symmetric. Blood pressure measurements were made with a mercury column according to American Heart Association Guidelines, with patients in the seated position and arm at heart level. Three readings were obtained and their average was treated as the blood pressure measure. Scatterplots show the bivariate relationship of TGF-β1 protein concentrations to systolic (Panels A and B) or diastolic (Panels C and D) blood pressure. Pearson correlations (r) and their associated P values are presented. The three boxes on the regression line show the predicted value of the outcome variable for subjects at the 10th, 50th, and 90th percentiles of the overall distribution of TGF-β1 protein. Numbers in parenthesis are the number of subjects studied. The symbols “o” and “x” are used to identify normotensive and hypertensive subjects.
Figure 3. Bivariate Relationship of Body Mass Index to Peripheral Blood TGF-β1 Protein Concentration in Black and White Subjects

Peripheral blood total transforming growth factor β1 (TGF-β1, ng/ml) level was measured after acid activation and neutralization of serum and using an isoform specific TGF-β1 ELISA, and transformed using the square root transformation to reduce the positive skewness and make the resulting distribution approximately symmetric. Height and weight were measured twice. Body mass index (BMI) was calculated as average weight (kilograms) divided by the square of average height (meters). Scatterplots show the bivariate relationship of TGF-β1 protein concentrations to BMI in black subjects (Panel A) and white subjects (Panel B). Pearson correlations (r) and their associated P values are presented. The three boxes on the regression line show the predicted BMI for subjects at the 10th, 50th, and 90th percentiles of the overall distribution of TGF-β1 protein. Numbers in parenthesis are the number of subjects studied. The symbols “o” and “x” are used to identify normotensive and hypertensive subjects.
### Table 1

**Characteristic of Subjects, Stratified by Race and Hypertension Status**

| Variable                        | Black Subjects | White Subjects | P Value $^\dagger$ |
|---------------------------------|----------------|----------------|-------------------|
|                                 | Normotensive   | Hypertensive   | Normotensive      | Hypertensive      |
|                                 | (N=116)        | (N=70)         | (N=79)            | (N=68)            |
| Sex (% male)                    | 37.1           | 21.4           | 40.5              | 52.9              | 0.002 |
| Age (yr)                        | 40.7±9.1       | 47.1±10.7      | 46.1±10.9         | 49.9±9.9          | 0.0001|
| BMI (kg/m$^2$) $^\dagger\ddagger$ | 29.4±6.6       | 31.2±6.1       | 27.4±5.5          | 29.4±5.5          | 0.004 |
| Systolic BP (mm Hg) $^\dagger\ddagger$ | 117±12         | 148±15         | 114±12            | 141±16            | 0.0001 |
| Diastolic BP (mm Hg) $^\dagger\ddagger$ | 75±8           | 91±9           | 75±8              | 90±9              | 0.0001 |
| Plasma glucose (mg/dl)          | 80.9±23.6      | 81.4±15.2      | 80.1±29.7         | 80.8±20.3         | 0.99 |
| Serum creatinine (mg/dl)        | 0.9±0.22       | 0.8±0.18       | 0.8±0.18          | 0.8±0.20          | 0.18 |
| PRA (ng/ml/hr) median (25th, 75th %-iles) | 1.3±1.4       | 0.8±1.1        | 2.1±1.5           | 1.7±1.6           | 0.0001 |
| Urinary Na Excretion (mEq/24hr) | 14±73          | 128±58         | 150±74            | 140±57            | 0.32 |
| Urinary Albumin/Creatinine Ratio (mg/g) median (25th, 75th %-iles) | 9.1±11.4 | 16.9±35.7 | 8.6±8.9 | 20.3±61.6 | 0.01 |
| Microalbuminuria (%)            | 3.9            | 9.2            | 2.7               | 7.8               | 0.27 |
| Metabolic Syndrome (%) $^\dagger\ddagger$ | 4.6           | 17.2           | 6.4               | 22.1              | 0.0008 |
| Number of Metabolic Syndrome Criteria | 1.1±1.1       | 2.0±0.9        | 1.0±1.0           | 1.9±1.0           | 0.001 |
| TGF-β1 Protein (ng/ml) median (25th, 75th %-iles) | 42±15          | 46±19          | 38±14             | 42±14             | 0.01 |

$^\ast$ Plus-minus values are mean±SD

$^\dagger$ P Value based on F-test for 1-way ANOVA for continuous variables (after log-transforming PRA and Urinary Albumin/Creatinine Ratio and square-root-transforming TGF-β1 Protein) or chi-square test of independence for binary variables.

$^\ddagger$ Height and weight were measured twice. Body mass index (BMI) was calculated as average weight (kilograms) divided by the square of average height (meters).

$^\ddagger\ddagger$ Blood pressure was measured with a mercury sphygmomanometer using standard American Heart Association Guidelines, with subjects in the seated position and arm at heart level. Three readings were obtained and their average was treated as blood pressure measure. Hypertension status was defined as an average BP ≥140/90 mmHg or being on antihypertensive medication. Individuals taking medication were withdrawn successfully from medication for at least 2 weeks prior to the study. Those whose BP exceeded 160/105 mmHg, before or after being withdrawn from medication, were not eligible.

$^\ddagger\ddagger$ Metabolic syndrome was defined according to the current recommended criteria of the National Cholesterol Education Program (Adult Treatment Panel [ATP] III).
Table 2

A: Predicted Difference (SE) in Outcomes Between Subjects at the 90th Percentile and Subjects at
the 10th Percentile of TGF-β1 Protein Distribution*

| Outcome                                      | Black Subjects | White Subjects | Race-by-
|                                             |                |                | TGF-β1
|                                              |                |                | interaction
|                                              |                |                | P Value
| PRA (ng/ml/hr) †                             | 1.17 (0.21)    | 0.09 (0.24)    | 0.0007
| P Value                                      | 0.0001         | 0.71           |          |
| Urine Na Excretion (mEq/24hr) †             | −18.8 (14.0)   | 20.0 (15.7)    | 0.06     |
| P Value                                      | 0.18           | 0.20           |          |
| Systolic BP (mm/Hg) † ‡                     | 9.5 (3.6)      | 2.3 (4.2)      |          |
| P Value                                      | 0.009          | 0.58           | 0.20     |
| Diastolic BP (mm/Hg) † ‡                    | 4.7 (2.2)      | 1.5 (2.5)      |          |
| P Value                                      | 0.03           | 0.56           | 0.34     |
| Pulse Pressure (mm/Hg) † ‡                  | 4.8 (2.4)      | 0.8 (2.8)      |          |
| P Value                                      | 0.05           | 0.77           | 0.29     |
| BMI (kg/m²) ‡                                | 2.5 (1.1)      | 1.2 (1.3)      |          |
| P Value                                      | 0.03           | 0.36           | 0.47     |
| Number of Metabolic Syndrome Criteria (0–5) || 0.82 (0.21)    | 0.42 (0.23)    | 0.20     |
| P Value                                      | 0.0001         | 0.07           |          |

| Outcome                                      | Black Subjects | White Subjects | P Value |
| Urine Albumin: Creatinine Ratio ≥30 mg/gm °   | 6.6 (1.4, 31.1)| 2.4 (0.3, 19.0)| 0.45    |
| P Value                                      | 0.02           | 0.39           |          |
| Metabolic Syndrome ° °                       | 4.5 (1.0, 19.9)| 3.0 (0.8, 11.6)| 0.69    |
| P Value                                      | 0.04           | 0.11           |          |

B: Predicted Odds Ratio (95 Percent Confidence Intervals) for Microalbuminuria or Metabolic
Syndrome Between Subjects at the 90th Percentile and Subjects at the 10th Percentile of TGF-β1 Protein
Distribution*

| Outcome                                      | Black Subjects | White Subjects | P Value |
| Urine Albumin: Creatinine Ratio ≥30 mg/gm °   | 6.6 (1.4, 31.1)| 2.4 (0.3, 19.0)| 0.45    |
| P Value                                      | 0.02           | 0.39           |          |

* Each outcome was analyzed in a regression analysis performed on the full sample that included race, log-transformed TGF-β1 protein, and a Race–by-TGF-β1 interaction term while controlling for sex and age; analyses, except those predicting BMI and metabolic syndrome, also controlled for BMI.

† Ordinary linear regression analysis.

‡ Blood pressure was measured with a mercury column using standard American Heart Association Guidelines, with subjects in the seated position and arm at heart level. Three readings were obtained and their average was treated as the blood pressure measure.

¶ Height and weight were measured twice. Body mass index (BMI) was calculated as average weight (kilograms) divided by the square of average height (meters).

∥ Metabolic syndrome was defined according to the current recommended criteria of the National Cholesterol Education Program (Adult Treatment Panel [ATP] III)20.

∫ Ordered probit regression analysis.
Logistic regression analysis.